Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer

期刊论文
出版模式：

开放获取
发表日期：

2024年4月16日

查看全文

Stefania Morganti,
Qingchun Jin,
Julie Vincuilla,
Ryan Buehler,
Sean Ryan,
Samantha Stokes,
Tonia Parker,
Elizabeth A. Mittendorf,
Tari A. King,
Anna Weiss,
Ann H. Partridge,
Brittany L. Bychkovsky,
Giuseppe Curigliano,
Nabihah Tayob,
Nancy U. Lin,
Judy E. Garber,
Sara M. Tolaney,
Filipa Lynce

摘要

Following the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast cancer after chemotherapy. However, optimal identification of high-risk patients who may derive benefit from this genomically-directed therapy is debated. In this study, we sought to characterize the real-world proportion of gBRCA1/2 PV carriers eligible for adjuvant olaparib according to the OlympiA criteria, and to compare clinicopathologic characteristics and outcomes between eligible and ineligible patients.